Angelalign Technology Wins Patent Ruling Against Align Technology in Germany

Angelalign Technology Inc. (6699.HK) has secured a critical legal victory in Europe after the Unified Patent Court’s Düsseldorf Local Division rejected Align Technology Inc.’s request for a preliminary injunction. The ruling allows Angelalign to continue utilizing its A7 Premolar Extraction Solution, providing significant operational certainty for its ongoing global expansion and market share growth.

The decision from the Düsseldorf Local Division represents a pivotal moment in the escalating intellectual property battles defining the clear aligner industry. By rejecting Align Technology Inc.’s (ALGN) request to preliminarily cease Angelalign’s use of the A7 Premolar Extraction Solution, the court has effectively neutralized a major strategic threat to Angelalign’s product continuity in key European markets. For a company that has already established itself as the #2 aligner provider globally, this legal reprieve is less about a single product and more about the right to compete in high-growth orthodontic segments.

A Strategic Firewall in the European Theatre

The litigation centered on allegations that Angelalign’s A7 tooth movement protocol infringed upon patents held by Align Technology Inc. Angelalign has maintained a categorical denial of these claims, asserting that its clinical innovations are the result of its own 23-plus years of research, and development. The court’s refusal to grant preliminary measures suggests that the threshold for a mandatory cease-and-desist was not met, a result that provides immediate relief to Angelalign’s clinical partners.

“We respect the Düsseldorf Local Division’s ruling and will continue to make our case that Angel has not violated any valid patents. We are grateful that the court decided not to grant Align’s request for preliminary measures. Angel takes intellectual property rights seriously and is careful not to infringe on legitimate patents.”
— Dr. Arno Riße, Attorney at Arnold Ruess Law Firm

This legal outcome arrives at a time when medtech companies are increasingly utilizing the Unified Patent Court to protect—or challenge—market dominance. For firms operating in this high-stakes environment, the ability to defend proprietary protocols is a prerequisite for maintaining investor confidence. As patent disputes become more frequent, many expanding enterprises are turning to specialized intellectual property law firms to navigate the complexities of cross-border injunctions and enforcement actions.

Richard Hirschland, Angelalign’s Chief Commercial Officer and SVP, emphasized that the company views this litigation as an opportunity rather than a setback. The firm is prepared to use the legal proceedings to validate its clinical success and strengthen its brand presence among orthodontists worldwide.

“We categorically deny the allegations of infringement and are fully confident in our position. We look forward to continue using the litigation to tell the Angel success story and help attract more customers to Angel around the world.”
— Richard Hirschland, CCO and SVP, Angelalign Technology Inc.

Scaling the Global Footprint: From China to North America

While the courtroom drama in Germany captures headlines, the broader financial narrative for Angelalign is one of aggressive, multi-continental scaling. Since launching its global expansion strategy in 2023, the company has extended its reach to over 60 countries and regions. This rollout is backed by a significant increase in physical infrastructure, most notably a new 52,000 sq. Ft. Manufacturing facility in the United States.

The move into the North American market, which began three years ago, is a cornerstone of the company’s mission to diversify its revenue streams and reduce regional dependency. This rapid expansion requires sophisticated operational oversight. Companies scaling at this velocity often require the expertise of supply chain management consultants to ensure that manufacturing capacity keeps pace with global demand without eroding margins through logistical bottlenecks.

Angelalign’s ability to treat over 2 million smiles is a testament to its “Complexity with Confidence” philosophy. The company’s portfolio—ranging from the award-winning angelButton and angelHook to the A6 mandibular advancement system and the angel KiD system—demonstrates a deep integration of digital technology and clinical expertise. This diverse product lineup serves as a buffer. even when specific features face legal scrutiny, the breadth of the ecosystem maintains the company’s market relevance.

Mitigating Risk in High-Growth MedTech

For institutional investors monitoring the 6699.HK ticker, the Düsseldorf ruling provides a necessary reduction in immediate regulatory and operational risk. In the medtech sector, a preliminary injunction can be catastrophic, potentially freezing revenue streams and disrupting doctor-patient workflows overnight. By securing this rejection, Angelalign has protected its ability to deliver its digital planning platform and orthodontic solutions without interruption.

The company’s long-term trajectory remains tethered to its capacity for innovation. With a history spanning over two decades, Angelalign has positioned itself not just as a manufacturer, but as a technology-driven service provider. The integration of the iOrtho™ digital planning platform into its service model illustrates a move toward a more holistic, software-enabled orthodontic experience, which typically commands higher stickiness among dental professionals.

However, the ongoing litigation serves as a reminder that growth in the clear aligner segment is inextricably linked to IP management. As Angelalign continues to expand its global footprint, the cost of defending its innovations will remain a key line item in its operational expenditure. Managing these legal headwinds requires proactive engagement with enterprise risk management services to ensure that litigation costs do not outpace the returns on new market entries.

As the industry moves toward more personalized, digital-first treatment, the battlelines between the world’s leading aligner companies will only become more clearly defined. Angelalign’s success in Düsseldorf is a significant tactical win that preserves its momentum as it seeks to solidify its position as a global leader in orthodontic innovation. To stay ahead of these shifting market dynamics, businesses should utilize the World Today News Directory to connect with the vetted B2B partners and legal experts essential for navigating a complex global economy.